Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-11-01

FDA Approved: COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM) — Supplemental Application (Noven Therapeutics, LLC)

View source ↗

Summary

The FDA approved a supplemental application for COMBIPATCH, the estradiol/norethindrone acetate transdermal system, developed by Noven Therapeutics, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COMBIPATCH (estradiol/norethindrone acetate transdermal system)

Snippet

SUPPL AP for COMBIPATCH (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM) (ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL SYSTEM)